Dragonfly, whose co-founders include MIT and UC Berkeley faculty, has boosted its total financing to $300m in round of undisclosed size led by Fidelity.
Dragonfly Therapeutics, a US-based immunotherapy developer exploiting research from Massachusetts Institute of Technology (MIT) and University of California (UC) Berkeley, has increased its overall equity and partnership financing to $300m.
The disclosure of its increased total financing follows a round of undisclosed size led by financial services and investment group Fidelity.
The company had raised a similarly undisclosed amount in 2017 from investors including pharmaceutical firm Celgene, the Duke of Bedford and members of the Disney family.
